Half-year report · HY
4583.TEDINET S100YW7X
Period2026-01-01 → 2026-06-30
Filed2026-08-13
StandardJapan GAAP
ConsolidatedNo
Data checks12 of 12 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥274m | 2026-01-01 → 2026-06-30 | Standalone | Net sales |
| Revenue | ¥593m | 2025-01-01 → 2025-12-31 | Standalone | Net sales (5-year summary) |
| Revenue | ¥252m | 2025-01-01 → 2025-06-30 | Standalone | Net sales |
| Operating income | −¥480m | 2026-01-01 → 2026-06-30 | Standalone | Operating income |
| Operating income | −¥537m | 2025-01-01 → 2025-06-30 | Standalone | Operating income |
| Ordinary income | −¥482m | 2026-01-01 → 2026-06-30 | Standalone | Ordinary income |
| Ordinary income | −¥989m | 2025-01-01 → 2025-12-31 | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥539m | 2025-01-01 → 2025-06-30 | Standalone | Ordinary income |
| Profit before tax | −¥482m | 2026-01-01 → 2026-06-30 | Standalone | Income before income taxes |
| Profit before tax | −¥539m | 2025-01-01 → 2025-06-30 | Standalone | Income before income taxes |
| Net income | −¥483m | 2026-01-01 → 2026-06-30 | Standalone | Profit loss |
| Net income | −¥983m | 2025-01-01 → 2025-12-31 | Standalone | Net income loss (5-year summary) |
| Net income | −¥540m | 2025-01-01 → 2025-06-30 | Standalone | Profit loss |
| Total assets | ¥1.9bn | at 2026-06-30 | Standalone | Assets |
| Total assets | ¥1.7bn | at 2025-12-31 | Standalone | Assets |
| Total assets | ¥2.0bn | at 2025-06-30 | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥341m | at 2026-06-30 | Standalone | Liabilities |
| Total liabilities | ¥605m | at 2025-12-31 | Standalone | Liabilities |
| Net assets / equity | ¥1.6bn | at 2026-06-30 | Standalone | Net assets |
| Net assets / equity | ¥1.1bn | at 2025-12-31 | Standalone | Net assets |
| Net assets / equity | ¥1.5bn | at 2025-06-30 | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥1.4bn | at 2026-06-30 | Standalone | Cash and deposits |
| Cash and deposits | ¥1.2bn | at 2025-12-31 | Standalone | Cash and deposits |
| Cash & equivalents | ¥1.4bn | at 2026-06-30 | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥1.2bn | at 2025-12-31 | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥1.5bn | at 2025-06-30 | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥2.1bn | at 2024-12-31v | Standalone | Cash and cash equivalents |
| Operating cash flow | −¥539m | 2026-01-01 → 2026-06-30 | Standalone | Net cash provided by used in operating activities |
| Operating cash flow | −¥936m | 2025-01-01 → 2025-12-31 | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥673m | 2025-01-01 → 2025-06-30 | Standalone | Net cash provided by used in operating activities |
| Investing cash flow | −¥4m | 2026-01-01 → 2026-06-30 | Standalone | Net cash provided by used in investment activities |
| Investing cash flow | −¥55m | 2025-01-01 → 2025-12-31 | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | ¥710m | 2026-01-01 → 2026-06-30 | Standalone | Net cash provided by used in financing activities |
| Financing cash flow | ¥133m | 2025-01-01 → 2025-12-31 | Standalone | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥85m | 2025-01-01 → 2025-06-30 | Standalone | Net cash provided by used in financing activities |
| EPS (basic) | ¥-6.62 | 2026-01-01 → 2026-06-30 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-14.47 | 2025-01-01 → 2025-12-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-7.97 | 2025-01-01 → 2025-06-30 | Standalone | Basic earnings loss per share (5-year summary) |
| Equity ratio | 81.9% | at 2026-06-30 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 64.1% | at 2025-12-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 76.9% | at 2025-06-30 | Standalone | Equity to asset ratio (5-year summary) |
| Shares issued | 78,940,200 | at 2026-06-30 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 68,453,800 | at 2025-12-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 68,053,800 | at 2025-06-30 | Standalone | Total number of issued shares (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 16
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | segment profit | 2026-01-01 → 2026-06-30 | −¥269m |
| Drug Discovery And Developmentreportable segment | segment profit | 2026-01-01 → 2026-06-30 | −¥369m |
| Drug Discovery Supportreportable segment | revenue | 2026-01-01 → 2026-06-30 | ¥274m |
| Drug Discovery Supportreportable segment | revenue external | 2026-01-01 → 2026-06-30 | ¥274m |
| Drug Discovery Supportreportable segment | segment profit | 2026-01-01 → 2026-06-30 | ¥159m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2026-01-01 → 2026-06-30 | ¥274m |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2026-01-01 → 2026-06-30 | ¥274m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2026-01-01 → 2026-06-30 | −¥210m |
| Reconciling Itemsreconciling | segment profit | 2025-01-01 → 2025-06-30 | −¥280m |
| Drug Discovery And Developmentreportable segment | segment profit | 2025-01-01 → 2025-06-30 | −¥396m |
| Drug Discovery Supportreportable segment | revenue | 2025-01-01 → 2025-06-30 | ¥252m |
| Drug Discovery Supportreportable segment | revenue external | 2025-01-01 → 2025-06-30 | ¥252m |
| Drug Discovery Supportreportable segment | segment profit | 2025-01-01 → 2025-06-30 | ¥139m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2025-01-01 → 2025-06-30 | ¥252m |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2025-01-01 → 2025-06-30 | ¥252m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2025-01-01 → 2025-06-30 | −¥257m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 430
| Item | Context | Value | Unit |
|---|---|---|---|
| Income taxes paid ope cf | InterimDuration_NonConsolidatedMember | -3240000 | JPY |
| Income taxes refund ope cf | Prior1InterimDuration_NonConsolidatedMember | 708000 | JPY |
| Income taxes refund ope cf | InterimDuration_NonConsolidatedMember | 376000 | JPY |
| Net cash provided by used in operating activities | Prior1InterimDuration_NonConsolidatedMember | -673006000 | JPY |
| Net cash provided by used in operating activities | InterimDuration_NonConsolidatedMember | -538823000 | JPY |
| Purchase of property plant and equipment inv cf | Prior1InterimDuration_NonConsolidatedMember | － | JPY |
| Purchase of property plant and equipment inv cf | InterimDuration_NonConsolidatedMember | -3733000 | JPY |
| Net cash provided by used in investment activities | Prior1InterimDuration_NonConsolidatedMember | － | JPY |
| Net cash provided by used in investment activities | InterimDuration_NonConsolidatedMember | -3733000 | JPY |
| Decrease in short term loans payable fin cf | Prior1InterimDuration_NonConsolidatedMember | -21000000 | JPY |
| Decrease in short term loans payable fin cf | InterimDuration_NonConsolidatedMember | -19200000 | JPY |
| Redemption of bonds fin cf | Prior1InterimDuration_NonConsolidatedMember | － | JPY |
| Redemption of bonds fin cf | InterimDuration_NonConsolidatedMember | -175000000 | JPY |
| Proceeds from issuance of common stock fin cf | Prior1InterimDuration_NonConsolidatedMember | 105678000 | JPY |
| Proceeds from issuance of common stock fin cf | InterimDuration_NonConsolidatedMember | 903771000 | JPY |
| Other net fin cf | Prior1InterimDuration_NonConsolidatedMember | － | JPY |
| Other net fin cf | InterimDuration_NonConsolidatedMember | -18000 | JPY |
| Net cash provided by used in financing activities | Prior1InterimDuration_NonConsolidatedMember | 84678000 | JPY |
| Net cash provided by used in financing activities | InterimDuration_NonConsolidatedMember | 709553000 | JPY |
| Net increase decrease in cash and cash equivalents | Prior1InterimDuration_NonConsolidatedMember | -588328000 | JPY |
| Net increase decrease in cash and cash equivalents | InterimDuration_NonConsolidatedMember | 166995000 | JPY |
| Cash and cash equivalents | Prior2YearInstant_NonConsolidatedMember | 2063280000 | JPY |
| Cash and cash equivalents | Prior1YearInstant_NonConsolidatedMember | 1205026000 | JPY |
| Cash and cash equivalents | Prior1InterimInstant_NonConsolidatedMember | 1474952000 | JPY |
| Cash and cash equivalents | InterimInstant_NonConsolidatedMember | 1372022000 | JPY |
| Raw materials | Prior1YearInstant_NonConsolidatedMember | 47103000 | JPY |
| Raw materials | InterimInstant_NonConsolidatedMember | 61186000 | JPY |
| Work in process | Prior1YearInstant_NonConsolidatedMember | 2309000 | JPY |
| Work in process | InterimInstant_NonConsolidatedMember | 11715000 | JPY |
| Revenues from external customers | Prior1InterimDuration_NonConsolidatedMember_jpcrp040300-ssr_E26096-000DrugDiscoveryAndDevelopmentReportableSegmentsMember | － | JPY |
| Revenues from external customers | Prior1InterimDuration_NonConsolidatedMember_jpcrp040300-ssr_E26096-000DrugDiscoverySupportReportableSegmentsMember | 251796000 | JPY |
| Revenues from external customers | Prior1InterimDuration_NonConsolidatedMember_TotalOfReportableSegmentsAndOthersMember | 251796000 | JPY |
| Revenues from external customers | Prior1InterimDuration_NonConsolidatedMember_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | Prior1InterimDuration_NonConsolidatedMember | 251796000 | JPY |
| Transactions with other segments | Prior1InterimDuration_NonConsolidatedMember_jpcrp040300-ssr_E26096-000DrugDiscoveryAndDevelopmentReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1InterimDuration_NonConsolidatedMember_jpcrp040300-ssr_E26096-000DrugDiscoverySupportReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1InterimDuration_NonConsolidatedMember_TotalOfReportableSegmentsAndOthersMember | － | JPY |
| Transactions with other segments | Prior1InterimDuration_NonConsolidatedMember_ReconcilingItemsMember | － | JPY |
| Transactions with other segments | Prior1InterimDuration_NonConsolidatedMember | － | JPY |
| Net sales | Prior1InterimDuration_NonConsolidatedMember_jpcrp040300-ssr_E26096-000DrugDiscoveryAndDevelopmentReportableSegmentsMember | － | JPY |
| Net sales | Prior1InterimDuration_NonConsolidatedMember_jpcrp040300-ssr_E26096-000DrugDiscoverySupportReportableSegmentsMember | 251796000 | JPY |
| Net sales | Prior1InterimDuration_NonConsolidatedMember_TotalOfReportableSegmentsAndOthersMember | 251796000 | JPY |
| Net sales | Prior1InterimDuration_NonConsolidatedMember_ReconcilingItemsMember | － | JPY |
| Net sales | Prior1InterimDuration_NonConsolidatedMember | 251796000 | JPY |
| Operating income | Prior1InterimDuration_NonConsolidatedMember_jpcrp040300-ssr_E26096-000DrugDiscoveryAndDevelopmentReportableSegmentsMember | -395868000 | JPY |
| Operating income | Prior1InterimDuration_NonConsolidatedMember_jpcrp040300-ssr_E26096-000DrugDiscoverySupportReportableSegmentsMember | 138866000 | JPY |
| Operating income | Prior1InterimDuration_NonConsolidatedMember_TotalOfReportableSegmentsAndOthersMember | -257002000 | JPY |
| Operating income | Prior1InterimDuration_NonConsolidatedMember_ReconcilingItemsMember | -279819000 | JPY |
| Operating income | Prior1InterimDuration_NonConsolidatedMember | -536822000 | JPY |
| Revenues from external customers | InterimDuration_NonConsolidatedMember_jpcrp040300-ssr_E26096-000DrugDiscoveryAndDevelopmentReportableSegmentsMember | － | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |